One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Replimune Group now clears that threshold, with a jump from 77 to 81 Friday.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's proprietary rating identifies market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks stacks up against all the other stocks in our database.
History reveals that the market's biggest winners often have an 80 or higher RS Rating as they launch their biggest price moves.
Replimune Group is not currently showing a potential buy point. See if the stock goes on to build a promising consolidation that could ignite a new run.
The company posted 0% EPS growth last quarter. Sales increased 0%. Look for the next report on or around Jul. 31.
The company earns the No. 212 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
